Ra Pharmaceuticals, Inc. is a company in the U.S. stock market and it is a holding in 36 U.S.-traded ETFs. RARX has around 3.7M shares in the U.S. ETF market. The largest ETF holder of RARX is the SPDR S&P Biotech ETF (XBI), with approximately 943.28K shares. Investors may also find of interest that the ETF with the largest allocation to RARX stock is ProShares Merger ETF (MRGR), with a portfolio weight of 2.55%. On average, U.S. ETFs allocate 0.40% of RARX to their portfolios.
Additionally, RARX is a favorite stock for Vanilla and Exchange-specific ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with RARX as a holding is the ALPS Medical Breakthroughs ETF (SBIO), with a return of 36.16%.